ATI-1428ATI-1428: Best in class potential CAM
ATI-1428 has entered IND enabling development
Derived from a novel chemical scaffold, ATI-1428 has shown strong in vitro and in vivo activity in a transgenic mouse model of hepatitis B virus (HBV) infection.1
Early in vivo data point to a differentiated mechanism of action (MOA) which prevents accumulation of empty capsids, unlike most CAMs, and potentially provides for a more targeted, productive clearance by the immune system.1
ATI-1428 has been identified as a 4th generation sub-nM potent compounds from a novel series of class II CAMs.1
Derived from a novel chemical scaffold, ATI-1428 shows safe and potent in vitro and in vivo activity, as well as an excellent PK and developability profile.1
Early in vivo data point to a differentiated MOA which prevents accumulation of empty capsids in the hepatocellular cytoplasm, unlike most CAMs, and potentially provides for a more targeted, productive clearance by the immune system.1
ATI-1428 displays strong antiviral activity against naturally occurring variants and low EC50 shift against variants associated with resistance to past and current CAMs.1
Why ATI-1428?
ATI-1428 results in more potent viral suppression than earlier generations, as measured by 2 key markers of HBV replication1
ATI-1428 deeply inhibits HBV replication and prevent cccDNA establishment without causing liver damage.1
Our CAMs have the potential to synergize with our ASPIN, ATI-2173, and target different stages of the HBV life cycle.1
ATI-1428 selected for unique mechanism of action1
- Traditional CAMs being developed by others induce retention of hepatitis B core antigen (HBcAg), while Antios’ proprietary novel CAMs (ATI-1428 and ATI-1645) do not1
- The retention of HBcAg empty capsid could be a clinical safety liability and a decoy for functional immune-based clearance1
- Competitor CAMs have on- and off-treatment ALT flares in their clinical programs1
Reference: 1. Data on file. Antios Therapeutics, Doylestown, PA.